European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
www.elsevier.com/locate/ejpb
Research paper
Disintegration of magnetic tablets in human stomach evaluated
by alternate current Biosusceptometry
Luciana A. Coráa, Madileine F. Américob, Ricardo Brandt Oliveirab, Oswaldo Baffac,
Rogério Moraesd, Fernando G. Romeirod, José Ricardo A. Mirandad,*
a
Department of Pharmacology, Biosciences Institute, UNESP, Botucatu-SP, Brazil
b
Department of Physiology, Medical School, USP, Ribeirão Preto-SP, Brazil
c
Department of Physics and Mathematics, FFCLRP, USP, Ribeirão Preto-SP, Brazil
d
Department of Physics and Biophysics, Biosciences Institute, UNESP, Botucatu-SP, Brazil
Received 4 April 2003; accepted in revised form 4 August 2003
Abstract
Oral administration is the most convenient route for drug therapy. The knowledge of the gastrointestinal transit and specific site for drug
delivery is a prerequisite for development of dosage forms. The aim of this work was to demonstrate that is possible to monitor the disintegration
process of film-coated magnetic tablets by multi-sensor alternate current Biosusceptometry (ACB) in vivo and in vitro. This method is based on
the recording of signals produced by the magnetic tablet using a seven sensors array and signal-processing techniques. The disintegration was
confirmed by signals analysis in healthy human volunteers’ measurements and in vitro experiments. Results showed that ACB is efficient to
characterize the disintegration of dosage forms in the stomach, being a research tool for the development of new pharmaceutical dosage forms.
q 2003 Elsevier B.V. All rights reserved.
Keywords: Disintegration time; Tablets; Biomagnetic measurement; Magnetic marker; Biosusceptometry
1. Introduction
Oral route is commonly used for drug administration and
solid pharmaceutical dosage forms are the most utilized,
since they present advantages such as: stability, ease
ingestion and commodity for the patients when compared
with other formulations [1].
The disintegration process consists in the release of
therapeutic agents contained in the solid dosage forms to be
absorbed and produces an effect in organism. This process is
dependent of time, pharmaceutical form, excipients and it is
related to the bioavailability of the drug. Therefore, if any
failure occurs, the dissolution and absorption of active
substance will be affected, damaging the pharmacological
effect [2].
Due to extreme importance for absorption of the
drugs, the disintegration must be evaluated before
* Corresponding author. Department of Physics and Biophysics,
Biosciences Institute – IBB, Laboratório de Biomagnetismo,
Universidade Estadual Paulista – UNESP, CXP 510, CEP 18618-000
Botucatu, São Paulo, Brazil. Tel.: þ 55-14-6802-6254; fax: þ 55-14-68026346.
E-mail address: jmiranda@ibb.unesp.br (J.R.A. Miranda).
0939-6411/$ - see front matter q 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0939-6411(03)00136-X
the commercialization of a new product. Although,
routinely in vitro tests are carried out a significative
correlation between these results and the biological situation
is difficult [3].
In vivo studies provide other informations about the
behavior of solid dosage forms in the gastrointestinal (GI)
tract since physiological variables, such as pH, motility, GI
transit and prandial state can interfere with the release
profile and absorption of many drugs [4,5]. Besides that,
specific sites for drug delivery assure the maximum
therapeutic usefulness, contributing to the rational development of new formulations [6].
To follow the transit and release characteristics of
pharmaceutical dosage forms in GI tract the g-scintigraphy is the standard method. However, it must be
emphasized that the use of radioisotopes requires
precaution to manipulate and to prepare the dosage
forms, besides the risks of exposition to ionizing
radiation in repeated studies. In addition, some countries
established restrictions to the use of radiation in studies
with human volunteers [7 –10]. The endoscopy also is
another method that can be used to observe the
disintegration of dosage forms in the stomach but
414
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
provides a discomfort to the volunteer because of its
invasiveness method [11].
As an alternative to the methodologies traditionally
utilized biomagnetic techniques are being employed to
study the behavior of solid pharmaceutical forms in the
human GI tract. The technique of magnetic marker
monitoring combined with the most sensitive magnetic
detector system, the superconducting quantum interference
device (SQUID) has been used to characterize, with great
accuracy, the GI transit and disintegration of magnetically
marked capsules [12 –15]. A multichannel-SQUID system
is precise, non-invasive and possesses high sensitivity, but
the need for liquid helium and a magnetically shielded
environment, as well as specially trained personnel makes it
difficult to be use in large scale.
Another biomagnetic system, the alternate current Biosusceptometry (ACB) is being utilized in investigations that
focus on studies about GI motility, such as: determination of
the orocaecal transit time, gastric emptying, esophageal
transit time, pharynx clearance and the gastric activity
contraction (GAC) through the ingestion of a test meal
magnetically marked [16 –20]. This methodology is based on
recordings obtained from a high magnetic susceptibility
material (ferrite – MnFe2O4) response to the application of an
alternated magnetic field. In this way, the signals originating
from the magnetic tracer and magnetic markers are detected
and analyzed using signals processing techniques.
A new instrumental approach through a multi-sensor
Biosusceptometric system allowing signal acquisition from
different positions was used. Comparative analysis between
the signals from magnetic markers (non-disintegrating
tablets) and magnetic tracers (disintegrating tablets) was
performed, thus making possible to follow the transition
between these magnetic forms, due to disintegration
process. This non-invasive method has the advantage of
high signal/noise ratio and low cost, with reasonable spatial
resolution.
Thus the main objective of this study was to employ a
multi-sensor biomagnetic system to characterize and
determine the disintegration time of a special solid dosage
form (magnetic tablets) in vivo and in vitro.
2. Materials and methods
2.1. Fundamentals of ACB
The ACB, with a single sensor, used in previous studies
involving the GI motility, consisted of two pair of coils
separated by a distance (baseline). Each pair of coils is
composed of the excitation coil (external) and a detection
coil (internal), this arrangement is also referred as a firstorder gradiometric configuration (Fig. 1a) [16 – 20].
The working principle, according to Faraday’s Induction
Law, is based on a double magnetic flux transformer with an
air nucleus, in which the pair (excitation/detection), located
Fig. 1. (a) Schematic diagram of ACB single sensor. The excitation and
detection coils are shown as well as the electronic equipment associated. (b)
Multi-sensor Biosusceptometry System showing the individual detection
coils and the single excitation coil.
more distant from magnetic material (ferrite), acts as
reference. Thus, the output signal is given by Eq. (1).
DF ¼ DFm 2 DFr
ð1Þ
where
DF ¼ total flux;
DFm ¼ measuring coil flux;
DFr ¼ reference coil flux:
Due to this configuration, when there is no magnetic
material near the system, the output signal is minimized.
With the approximation of any magnetic mass, an unbalance
in the output signal occurs and the temporal variation of the
magnetic flux is detected as an electromotive force, a phase
sensitive detection (‘lock-in’) is used to improve
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
the sensitivity (Fig. 1a). This system is sensitive to distance
variations between the detector coil and the magnetic
material, thus this technique is very sensitive to movement
of the ferrite inside the organ as showed in the studies of
GAC [17].
2.2. Multi-sensor ACB
The difference between the multi-sensor system and the
previously utilized is that the new arrangement uses only a pair
of excitation coil (f ¼ 11 cm) and seven pairs of detection
coils (f ¼ 3.5 cm) in the first-order gradiometric configuration, coaxially arranged (Fig. 1b). This system is fixed in a
vertical support with adjustment to be positioned on the area
corresponding to the gastric projection of human subject.
The signals were acquired through the use of seven ‘lockin’ amplifiers (Stanford Research Systems) digitalized to
an A/D board of 16 bits (PCI-MIO-16XE-10, National
Instruments Inc.) with a microcomputer.
The signals generated by the magnetic tablets were
acquired in seven distinct points distributed on the
abdominal wall (gastric projection). The real time visualization of these signals allows the knowledge of ferrite
distribution in the stomach.
The study of disintegration is based in the fact that, after
the swallowing, the signals of magnetic tablets are given by a
punctual source (magnetic marker) that, when disintegrating,
it will be interpreted as a magnetic tracer in which the
particles are dispersed in a larger volume. Thus, changes in
the magnetic signals recorded simultaneously by the sensors
provide temporal data about spatial localization and also
disintegration process in the gastric region. These modifications can be observed through a change in the baseline
level between the sensors and in intensity of GAC in each
sensor before and after the disintegration process. Consequently, this will cause more sensors to recording the
contraction activity, indicating the distribution of magnetic
material. Hence, by analysis of simultaneous recordings, the
coating dissolution time (CDT) and the disintegration time
(DT) can be determined.
415
spray-drying with a solution of gastrosoluble polymer –
Eudragitw E100 (Röhm, Germany) [22].
2.4. In vitro study
For this experiment 12-coated magnetic tablets were used.
Initially a beaker was immersing in a glass vessel containing
4.0 l of water prewarming. This beaker containing 1.5 l of
acid solution (pH ¼ 1.2; 0.1 Eq.l21 HCl) was maintained at
378C with the aid of a thermostat. After that, the apparatus
was positioned in front of the multi-sensor Biosusceptometry
system. A video camera (Samsungw, Japan) was used to
obtain the correspondent images of the tablets in the solution,
aiming to correlate the digitalized images with acquired
signals. Each of the magnetic tablets was introduced in the
solution, simulating the swallow by the volunteer, and
signals were acquired until the complete disintegration. The
acid solution was replaced before each measurement.
To observe the response to the movement of punctual
sources in the multi-sensor system magnetic, gastroresistent
tablets were moved along the axis and transversal to the
gradiometer.
2.5. In vivo study
The study was done in the Biomagnetism Laboratory,
Department of Physics and Biophysics – Institute of
Biosciences after approval by the Ethic Committee in
Research of the Medical School – Universidade Estadual
Paulista (UNESP). Non-symptomatic 12 healthy volunteers,
2.3. Preparation of magnetic tablets
The tablets used in this study can be considering a new
pharmaceutical dosage due its characteristics. These dosage
forms were obtained by direct compression from 1.0 g of
ferrite powder (MnFe2O4; 80 # f # 125 mm) mixed with
0.5 g of microcrystalline cellulose (Merck, Germany), 0.01
g of magnesium stearate (Merck, Germany) and 0.1 g of
effervescent mixture (SmithKline Beecham, Brazil). The
ferrite is an inert material that is not absorbed by the GI
tract, harmless to the organism and, therefore without side
effects, endowing the tablet as a magnetic marker [21]. The
effervescent mixture was the choice to provide fast
disintegration. Magnetic tablets weighing 1.52 g, 1.0 cm
of diameter and density of 2.03 g/cm3 were coated by
Fig. 2. Schematic positioning of sensors in gastric projection in the volunteers
(Modified of Netter – Atlas of Human Anatomy – CD ROM 1998).
416
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
of both sex and aged between 21 and 40 years old were
selected. Informed consent was obtained from all of them.
The multi-sensor Biosusceptometry System was positioned on the volunteers abdomen, in orthostatic position, in
the correspondent region to gastric projection, considering
the xiphoid process and the umbilicus as anatomic
references (Fig. 2). The human volunteers, after an
overnight fasting, already positioned, swallowed a magnetic
dosage with 200 ml of water. The acquisition of signals was
done, concomitantly, during 15 min.
To quantify the disintegration process in vitro and in
vivo the CDT and DT were determined.
The interval that corresponds to the CDT indicates the
period in which there is no release of magnetic material
(ferrite) and was determined from the arrival of the
magnetic tablets in the acid solution or in the volunteers’
stomach, until the onset of disintegration process.
DT corresponds to the interval between the onset and
complete disintegration of the magnetic tablet. To dissolve
the coating, the dosage form remains in contact with the acid
solution or gastric fluid that promotes a fast disintegration,
by the action of the excipients.
2.6. Data analysis
The magnetic signals, recorded with acquisition frequency of 10 Hz/channel and stored in ASCII format, were
analyzed in MatLab (Mathworks, Inc.) using bi-directional
Butterworth filter with 150 mHz cutoff frequency. The
frequency analysis was done by fast fourier transform.
3. Results
3.1. In vitro measurement
The Fig. 3 shows the image sequence correlated with
magnetic signals acquired during the magnetic tablet
Fig. 3. Illustration of image sequence correlated with magnetic signals of tablet disintegration process in vitro. Each image has an instant correspondent in
recording and the arrows a, b, c, indicated respectively, the arrival, onset and complete disintegration. The arrow b1 indicate an intermediary instant of
disintegration process. The numbers of sensors followed the same configuration showed in Fig. 2.
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
disintegration process in acid solution. The arrows a, b, c
indicates respectively, the arrival, the onset and complete
disintegration of magnetic tablets.
The CDT was determined by the time interval between
the arrows a, b and corresponds to the period in which the
pharmaceutical dosage form remains solid. DT was
determined for the interval between arrows b, c.
The arrival of magnetic dosage form in the acid solution
(arrow a) shows that the sensor located near the tablet presents
high intensity of magnetic signal (sensor 5). In the recorded
signal, it was observed a period of stability during the CDT in
which does not occur the ferrite release, indicating a lag time
until the beginning of magnetic tablet disintegration.
With the reduction of coating layer, caused by action of
the acid solution, the tablet disintegration begins (arrow b).
At this moment, a strong decline of intensity of magnetic
signal at the nearer sensors (sensors 1 and 5) is observed,
417
while the signal intensity at the more distant sensor (sensor
2) increases quickly. This occurs because the spreading of
ferrite in the recipient. The DT was calculated in this period
of magnetic signals alterations. The arrow c indicates the
complete disintegration process and the signal return to
stability, but with different basal level compared with initial
phase. All this process can be followed by the correspondent
images (Fig. 3).
The Fig. 4 presents the CDT and DT for all the in vitro
measurements and inset illustrates the CDT and DT
obtained. The averages were significantly different for
P , 0:01 (Student’s t-test).
3.2. In vivo measurement
The Fig. 5 is a typical example of magnetic signals
obtained in a measurement with human volunteers.
Fig. 4. CDT and DT of the magnetopharmaceutical in vitro experiments. The inset illustrates the average values for times.
418
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
Fig. 5. Example of magnetic signals acquired in subject measurement. Observe basal level variation between the sensors and the recording of GAC in real time. The
numbers of sensors followed the same configuration illustrated in Fig. 2. The arrows a, b and c indicate, respectively, the arrival, onset and complete disintegration.
The arrows a, b, c indicate respectively, the arrival, the onset
and complete disintegration. The determination of CDT and
DT for in vivo measurements followed by the same
parameters used in vitro measurements.
Based on the position of the sensors (Fig. 2), it was
observed in all the volunteers that the magnetic tablet was
deposited in the projection region of the distal stomach. The
arrival of magnetic tablet (arrow a) was verified through the
intense alteration of basal level in the signal of the sensor
positioned in that region (sensor 5) and confirmed by the
transit recording of magnetic dosage during its passage to
the sensor in the proximal region (sensor 3).
Arrow b indicates the onset of magnetic tablet disintegration. The magnetic signal of the sensor located near the
tablet (sensor 5) had strong decline of intensity and in the
most distant sensors (sensors 1 and 3) occurs an increase of
intensity indicating the distribution of magnetic material in
the organ. The complete disintegration process is indicated
by arrow c and the magnetic signal remain stable, but as
observed in the in vitro measurement, there was different
basal level characterizing the distribution of ferrite for the
disintegration process.
The GAC with typical frequency of three cycles/minute
also is an important indication of magnetic tablet
disintegration. The GAC was registered in real time
showing that, before the disintegration process
the amplitude of contractions was more intense in the distal
sensors (1 and 5) than the proximal sensor (sensor 3). After
the complete disintegration, must be observed that
the recorded signal by proximal sensor (sensor 3) shows
the GAC with a quick increase of amplitude due to
distribution of ferrite. The GAC and the basal level variation
between the sensors characterize the tablet disintegration,
indicating the transition between a magnetic marker to
magnetic tracer.
In Fig. 6 are presented the CDT and DT for all the human
measurements and the inset shows the mean values obtained
for these times. The averages were not significantly different
to P , 0:05 (Student’s t-test).
4. Discussion
The new multi-sensor biosusceptometric system provided a significative improvement in the sensitivity and in
the spatial resolution, compared to the system used in the
previous investigations [16 – 20]. This is the first study using
multi-sensor ACB to investigate the behavior of punctual
sources and through the recording of alterations in the basal
level and the intensity of the magnetic signal originating
from different sensors, being able to characterize the
magnetic tablets disintegration. The performance of magnetic signals indicating the ferrite release was similar to
the in vitro experiments and for the in vivo measurement,
showing accuracy of ACB to record the disintegration
process.
Film coating is much used in conventional dosage forms
and the CDT indicated how long the pharmaceutical form
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
419
Fig. 6. CDT and DT of the magnetopharmaceutical in vivo measurements. The inset illustrates the average values for times.
remained solid in the gastric fluid or acid solution. It is an
important parameter in the development of a drug delivery
system, including gastroretentive dosage forms and colonspecific drug delivery [23]. In these cases, an adequate and
uniform coating is indispensable to promote the drug
delivery in a specific site at the GI tract [24]. The CDT of
magnetic tablets verified in both the in vitro and in vivo
measurements were equivalent.
Another parameter with important consequences in the
drug delivery of solid dosage forms is the DT that can be
influenced by GAC in the subject measurements. The
destructive action of the motility interferes in the solid
forms disintegration and can affect the bioavailability of
the drug [4]. The motility pattern is characterized according
to the prandial state and the presence or absence of food can
affect considerably the release and absorption of many
therapeutic agents. In this manner, the ACB could be
employed in future studies to evaluate the behavior of
magnetic dosage forms in different prandial state, to
compare the effects of fasting and postprandial motility in
disintegration process.
The success for the rational development of new
formulations depends on the knowledge of physiological
variables of GI tract that act in the behavior of the release
systems [25]. It is indispensable the use of methodologies to
investigate the solid dosage forms in GI tract without
interfere the organ normal physiology.
For this reason, the pharmacoscintigraphy is a
standard methodology used for assessing the disintegration rate of capsules and tablets besides allowing
the correlation with pharmacokinetics data [11].
Recently, the development of new technologies like
the multichannel-SQUID systems make possible the
monitoring and the study of disintegration of magnetic
dosage forms allowing to obtain information about those
formulations in the GI tract [14].
420
L.A. Corá et al. / European Journal of Pharmaceutics and Biopharmaceutics 56 (2003) 413–420
This study shown that the multi-sensor ACB is another
biomagnetic technique that, although, does not have the
sensibility and the spatial resolution of the SQUID was able
to characterize efficiently the magnetic tablets disintegration
with the advantage of having a lower cost, easier operation
and portability.
The multi-sensor ACB can be used in tests to evaluate
efficacy of super-disintegrants potentials in new pharmaceutical dosage contends magnetic material. Besides that,
this technique in combination with pharmacokinetic studies
could be providing information about the GI transit and
disintegration of oral dosage forms and subsequent drug
absorption.
The development of a system involving more sensors will
contribute for new applications of multi-sensor ACB and an
association of new magnetic devices, like magnetoresistive
magnetometer, can improve the accuracy and sensitivity of
this methodology. The multi-sensor ACB also is a research
tool that can be used in future acquisition of magnetic images
allowing to visualize the disintegration process in vivo.
In this way, the physical characteristics that impaired the
comparison between the magnetic tablet and the conventional solid form could be overcome. This improvement
would elevate the magnetic dosage to the condition of
‘magnetopharmaceuticals’ in analogy to the radiopharmaceuticals utilized by scintigraphy.
In summary, our data showed that multi-sensor ACB has
a great capability to study the dosage forms disintegration
both in vitro and in vivo. Moreover, ACB is a non-invasive
technique and radiation-free, that a new approach for
investigation of drug delivery systems in the human GI tract.
Acknowledgements
Financial support was supplied by Fundação de Amparo
à Pesquisa do Estado de São Paulo – FAPESP, Brazil.
Eudragitw samples supplied by Almapal S/A – São Paulo,
Brazil. Technical Support Mr Murilo Stelzer.
References
[1] S.V. Sastry, J.R. Nyshadham, J.A. Fix, Recent technological advances
in oral drug delivery – a review, Pharm. Sci. Tech. Today 3 (2000)
138–145.
[2] C.D. Melia, S.S. Davis, Review article: mechanisms of drug release
from tablets and capsules. I: Disintegration, Aliment. Pharmacol.
Ther. 3 (1989) 223– 232.
[3] M. Zahirul, I. Khan, Dissolution testing for sustained or controlled
release oral dosage forms and correlation with in vivo data: challenges
and opportunities, Int. J. Pharm. 140 (1996) 131–143.
[4] M. Kamba, Y. Seta, A. Kusai, M. Ikeda, K.A. Nishimura, A. unique,
dosage form to evaluate the mechanical destructive force in the
gastrointestinal tract, Int. J. Pharm. 208 (2000) 61 –70.
[5] V. Pillay, R. Fassihi, In vitro release modulation from crosslinked
pellets for site-specific drug delivery to gastrointestinal tract.
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
I. Comparison of pH-responsive drug release and associated kinetics,
J. Control. Release. 59 (1999) 229–242.
J.T. Fell, Targeting of drugs and delivery systems to specific sites in
the gastrointestinal tract, J. Anat. 189 (1996) 517 –519.
G.A. Digenis, E.P. Sandefer, R.C. Page, W.J. Doll, Gamma
scintigraphy: an envolving technology in pharmaceutical formulation
development – Part 1, Pharm. Sci. Tech. Today 1 (1998) 100– 107.
G.A. Digenis, E.P. Sandefer, R.C. Page, W.J. Doll, Gamma
scintigraphy: an envolving technology in pharmaceutical formulation
development – Part 2, Pharm. Sci. Tech. Today 1 (1998) 160– 165.
A.C. Perkins, C.G. Wilson, M. Frier, P.E. Blackshaw, D. Juan, R.J.
Dansereaus, S. Hathaways, Z. Li, P. Long, R.C. Spiller, Oesophageal
transit, disintegration and gastric emptying of a film-coated
risedronate placebo tablet in gastro-oesophageal reflux disease and
normal control subjects, Aliment. Pharmacol. Ther. 15 (2001)
115 –121.
N. Billa, K. Yuen, M. Khader, A. Omar, Gamma-scintigraphic study
of the gastrointestinal transit and in vivo dissolution of a controlled
release diclofenac sodium formulation in xanthan gum matrices, Int.
J. Pharm. 201 (2000) 109–120.
I.R. Wilding, A.J. Coupe, S.S. Davis, The role of g-scintigraphy in
oral drug delivery, Adv. Drug Deliv. Rev. 46 (2001) 103–124.
W. Weitschies, J. Wedemeyer, R. Stehr, L. Trahms, Magnetically
marked pharmaceutical dosage forms to monitor gastrointestinal
transit by biomagnetic measurements, Pharm. Phamacol. Lett. 1
(1991) 45– 48.
W. Weitschies, R. Kötitz, D. Cordini, L. Trahms, High-resolution
monitoring of the gastrointestinal transit of a magnetically marked
capsule, J. Pharm. Sci. 86 (1997) 1218–1222.
W. Weitschies, M. Karaus, D. Cordini, L. Trahms, J. Breitkreutz, W.
Semmler, Magnetic marker monitoring of disintegrating capsules,
Eur. J. Pharm. Sci. 13 (2001) 411–416.
Z. Hu, S. Mawatari, N. Shibata, K. Takada, H. Yoshikawa, A.
Arakawa, Y. Yosida, Application of a biomagnetic measurement
system (BMS) to the evaluation of gastrointestinal transit of Intestinal
pressure-controlled colon delivery capsules (PCDCs) in human
subjects, Pharm. Res. 17 (2000) 160–167.
J.R.A. Miranda, O. Baffa, R.B. Oliveira, N.M. Matsuda, An AC
biosusceptometer to study gastric emptying, Med. Phys. 19 (1992)
445 –448.
J.R.A. Miranda, R.B. Oliveira, P.L. Sousa, F.J.H. Braga, O. Baffa, A
novel biomagnetic method to study gastric antral contractions, Phys.
Med. Biol. 42 (1997) 1791–1799.
O. Baffa, R.B. Oliveira, J.R.A. Miranda, L.E.A. Troncon, Analysis
and development of AC biosusceptometer for orocaecal transit time
measurements, Med. Biol. Eng. Comput. 33 (1995) 353–357.
C.A. Miquelin, F.J. Braga, R.O. Dantas, R.B. Oliveira, O. Baffa,
Pharyngeal clearance and pharyngeal transit time determined by a
biomagnetic method in normal humans, Dysphagia 16 (2001)
308 –312.
N.A. Daghastanli, F.J. Braga, R.B. Oliveira, O. Baffa, Oesophageal
transit time evaluated by a biomagnetic method, Physiol. Meas. 19
(1998) 413 –420.
M. Forsman, Magnetic substances and externally applied field in:
W. Andrä, H. Nowak (Eds), Magnetism in Medicine, Wiley-VCH,
Berlin, Germany, 1998, pp. 430 –445.
M. Dittgen, M. Durrani, K. Lehmann, Acrylic polymers: a review of
pharmaceutical applications, STP Pharm. Sci. 7 (1997) 403 –437.
C.S. Leopold, Coated dosage forms for colon-specific drug delivery,
Pharm. Sci. Tech. Today 2 (1999) 197 –204.
S. Obara, J.W. McGinity, Properties of free films prepared from
aqueous polymers by a spraying technique, Pharm. Res. 11 (1994)
1562–1567.
S.P. Newman, P.H. Hirst, I.R. Wilding, New developments in
radionuclide imaging for assessing drug delivery in man, Eur.
J. Pharm. Sci. 18 (2003) 19–22.